Form 4: Standard BioTools Executive Sells Shares to Cover Tax Obligations from RSU Vesting

Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc., sold a total of 25,374 shares of common stock over two days in May 2025 to satisfy tax obligations related to the vesting of restricted stock units.

Summary

• Sean Mackay, the Senior Vice President and Chief Business Officer of Standard BioTools Inc. (LAB), reported two transactions involving the sale of company common stock.
• On May 21, 2025, Mr. Mackay disposed of 12,838 shares of common stock at a weighted average price of $1.03 per share, with prices ranging from $1.015 to $1.05.
• On May 22, 2025, an additional 12,536 shares were sold at a weighted average price of $1.002 per share, with prices ranging from $0.9403 to $1.03.
• These sales were conducted to satisfy tax obligations incurred upon the vesting of restricted stock units (RSUs) that were granted to Mr. Mackay on March 21, 2025.
• Following these transactions, Mr. Mackay beneficially owns 856,293 shares of Standard BioTools common stock.
• The transactions were made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged sale plan.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction is a routine, non-discretionary sale to cover tax liabilities from RSU vesting, which is a common practice and not indicative of a change in management's view of the company's prospects.

Negatives

• The transactions represent a reduction in direct beneficial ownership by a key executive, although the reason for sale is tax-related and not discretionary.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This Form 4 filing is a routine disclosure of an insider stock transaction and does not provide broader insights into industry trends or competitive landscape for the biotechnology or life sciences tools sector.

Stakeholder Impact

• Shareholders: The sale represents a minor dilution of the executive's direct ownership, but it is a standard practice for tax purposes related to equity compensation and does not necessarily signal a lack of confidence.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

Keywords

Standard BioTools, LAB, Sean Mackay, Form 4, SEC filing, insider trading, stock sale, restricted stock units, RSU vesting, tax obligations, Rule 10b5-1 plan